{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:46:25Z","timestamp":1791773185432,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-165954"],"award-info":[{"award-number":["PJT-165954"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.thromres.2024.03.024","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T16:43:55Z","timestamp":1711385035000},"page":"71-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study"],"prefix":"10.1016","volume":"237","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6005-4006","authenticated-orcid":false,"given":"Antonios","family":"Douros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian B.","family":"Filion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Renoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.thromres.2024.03.024_bb0005","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the Management of Patients with Atrial Fibrillation","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"issue":"38","key":"10.1016\/j.thromres.2024.03.024_bb0010","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.thromres.2024.03.024_bb0015","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/heartjnl-2016-310586","article-title":"Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation","volume":"103","author":"Alonso","year":"2017","journal-title":"Heart"},{"issue":"10","key":"10.1016\/j.thromres.2024.03.024_bb0020","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jacc.2018.01.009","article-title":"Non-vitamin K antagonist Oral anticoagulants and risk of serious liver injury","volume":"71","author":"Douros","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.thromres.2024.03.024_bb0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/eut263","article-title":"Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF)","volume":"16","author":"Kirchhof","year":"2014","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.thromres.2024.03.024_bb0030","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/bcp.15046","article-title":"Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease","volume":"88","author":"Douros","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.thromres.2024.03.024_bb0035","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1056\/NEJMra1011170","article-title":"The coagulopathy of chronic liver disease","volume":"365","author":"Tripodi","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.thromres.2024.03.024_bb0040","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/hep.21303","article-title":"Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management","volume":"44","author":"Caldwell","year":"2006","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.thromres.2024.03.024_bb0045","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0091270008324179","article-title":"Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment","volume":"48","author":"Stangier","year":"2008","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.thromres.2024.03.024_bb0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bcp.12054","article-title":"Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"76","author":"Kubitza","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.thromres.2024.03.024_bb0055","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/jcph.550","article-title":"An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics","volume":"55","author":"Mendell","year":"2015","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.thromres.2024.03.024_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088390","article-title":"Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis","volume":"9","author":"Potze","year":"2014","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.thromres.2024.03.024_bb0065","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.thromres.2024.03.024_bb0070","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2024.03.024_bb0075","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.thromres.2024.03.024_bb0080","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.thromres.2024.03.024_bb0085","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1016\/j.jacc.2019.04.052","article-title":"Direct Oral anticoagulants in patients with atrial fibrillation and liver disease","volume":"73","author":"Lee","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.thromres.2024.03.024_bb0090","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCULATIONAHA.122.060687","article-title":"Comparative effectiveness and safety of direct Oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a Nationwide cohort study","volume":"147","author":"Lawal","year":"2023","journal-title":"Circulation"},{"issue":"9921","key":"10.1016\/j.thromres.2024.03.024_bb0095","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.thromres.2024.03.024_bb0100","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: clinical practice research datalink (CPRD) aurum","volume":"48","author":"Wolf","year":"2019","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.thromres.2024.03.024_bb0105","series-title":"Medicines and Healthcare Products Regulatory Agency","year":"2021"},{"key":"10.1016\/j.thromres.2024.03.024_bb0110","unstructured":"RAMQ - Public Prescription Drug Insurance Plan. (http:\/\/www.ramq.gouv.qc.ca\/en\/citizens\/prescription-drug-insurance\/Pages\/eligibility.aspx)."},{"issue":"3","key":"10.1016\/j.thromres.2024.03.024_bb0115","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1161\/CIRCOUTCOMES.113.000817","article-title":"Stratifying the risks of oral anticoagulation in patients with liver disease","volume":"7","author":"Efird","year":"2014","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"issue":"6","key":"10.1016\/j.thromres.2024.03.024_bb0120","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005307","article-title":"Liver cirrhosis in patients with atrial fibrillation: would Oral anticoagulation have a net clinical benefit for stroke prevention?","volume":"6","author":"Kuo","year":"2017","journal-title":"J. Am. Heart Assoc."},{"issue":"8","key":"10.1016\/j.thromres.2024.03.024_bb0125","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1161\/01.STR.0000174293.17959.a1","article-title":"Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10","volume":"36","author":"Kokotailo","year":"2005","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.thromres.2024.03.024_bb0130","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.thromres.2005.06.015","article-title":"Accuracy of coding for possible warfarin complications in hospital discharge abstracts","volume":"118","author":"Arnason","year":"2006","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.thromres.2024.03.024_bb0135","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1503\/cmaj.121218","article-title":"Rates of hemorrhage during warfarin therapy for atrial fibrillation","volume":"185","author":"Gomes","year":"2013","journal-title":"CMAJ"},{"issue":"5","key":"10.1016\/j.thromres.2024.03.024_bb0140","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/sim.4780080504","article-title":"Flexible regression models with cubic splines","volume":"8","author":"Durrleman","year":"1989","journal-title":"Stat. Med."},{"issue":"3","key":"10.1016\/j.thromres.2024.03.024_bb0145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"issue":"2","key":"10.1016\/j.thromres.2024.03.024_bb0150","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.thromres.2024.03.024_bb0155","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"446","key":"10.1016\/j.thromres.2024.03.024_bb0160","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J. Am. Stat. Assoc."},{"issue":"6","key":"10.1016\/j.thromres.2024.03.024_bb0165","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial","volume":"293","author":"Albers","year":"2005","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.thromres.2024.03.024_bb0170","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.jacc.2018.03.023","article-title":"Oral anticoagulation in patients with liver disease","volume":"71","author":"Qamar","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.thromres.2024.03.024_bb0175","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/sim.4780100409","article-title":"Channeling bias in the interpretation of drug effects","volume":"10","author":"Petri","year":"1991","journal-title":"Stat. Med."},{"issue":"23","key":"10.1016\/j.thromres.2024.03.024_bb0180","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023428","article-title":"Disparities in anticoagulation use by race and ethnicity in long-term care residents with atrial fibrillation","volume":"10","author":"Kapoor","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"12","key":"10.1016\/j.thromres.2024.03.024_bb0185","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jamacardio.2018.3945","article-title":"Association of Race\/ethnicity with Oral anticoagulant use in patients with atrial fibrillation: findings from the outcomes registry for better informed treatment of atrial fibrillation II","volume":"3","author":"Essien","year":"2018","journal-title":"JAMA Cardiol."},{"issue":"5","key":"10.1016\/j.thromres.2024.03.024_bb0190","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-048839","article-title":"Socioeconomic inequality in oral anticoagulation therapy initiation in patients with atrial fibrillation with high risk of stroke: a register-based observational study","volume":"11","author":"Lunde","year":"2021","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.thromres.2024.03.024_bb0195","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40264-019-00842-1","article-title":"Comparative effectiveness and safety of direct Oral anticoagulants in patients with atrial fibrillation: a systematic review and Meta-analysis of observational studies","volume":"42","author":"Douros","year":"2019","journal-title":"Drug Saf."},{"issue":"4","key":"10.1016\/j.thromres.2024.03.024_bb0200","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40262-013-0034-0","article-title":"Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment","volume":"52","author":"Graff","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.thromres.2024.03.024_bb0205","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026863","article-title":"Prescribing trends of Oral anticoagulants in US patients with cirrhosis and Nonvalvular atrial fibrillation","volume":"12","author":"Simon","year":"2023","journal-title":"J. Am. Heart Assoc."},{"issue":"2","key":"10.1016\/j.thromres.2024.03.024_bb0210","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.thromres.2015.06.007","article-title":"Determinants of oral anticoagulation control in new warfarin patients: analysis using data from clinical practice research datalink","volume":"136","author":"Macedo","year":"2015","journal-title":"Thromb. Res."},{"issue":"5","key":"10.1016\/j.thromres.2024.03.024_bb0215","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/clc.22948","article-title":"Rationale, design, and preliminary results of the Quebec warfarin cohort study","volume":"41","author":"Perreault","year":"2018","journal-title":"Clin. Cardiol."},{"issue":"5","key":"10.1016\/j.thromres.2024.03.024_bb0220","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with EACTS","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur. Heart J."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938482400104X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938482400104X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T05:20:21Z","timestamp":1714108821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004938482400104X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":44,"alternative-id":["S004938482400104X"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.03.024","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}